Skip to content
value.today
CEL-SCI Corporation logo

CEL-SCI Corporation

CVM
$26 Mmarket cap on Oct 30, 2026-79.9% since Jan 2024
Compare
World rank
#23,462
Revenue
—
For year ending September-2025
Net income
$-25 M
SEC filing
Employees
—

CEL-SCI Corporation in brief

CEL-SCI Corporation is a listed company in the Biotechnology industry, based in Vienna, Virginia, USA. It was founded in 1983. Its market value was $26 M on 30 October 2026, which makes it the 23,462nd largest listed company in the world and the 4,073rd largest in the USA on this site. Geert R. Kersten is its chief executive. Its shares trade under the symbol CVM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CEL-SCI Corporation

Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.

Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration (FDA). Multikine has also been referred to as Leukocyte Interleukin Injection (LI). Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

CEL-SCI Corporation timeline

4 events, 1983–2013
  1. 1983
  2. 🏁
    · approximate
    Incorporated as CEL-SCI Corporation
  3. 1996
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 1997
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2013
  8. •
    Legal Entity Identifier issued
    LEI 549300FIWOFSETIVMI17 registered.

Events of CEL-SCI Corporation from the GLEIF LEI register, SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$124 M$249 M$373 M$498 M2020202120222023202420252026

World rank over time

▼ down 9,985 places since 2020
2020-01-01: #13493#13,49320202021-01-01: #11558#11,55820212022-01-07: #17237#17,23720222022-12-25: #21712#21,71220222023-07-30: #22653#22,65320232024-01-05: #20073#20,07320242026-03-08: #11495#11,49520262026-08-01: #21080#21,08020262026-10-08: #22390#22,39020262026-10-30: #23478#23,4782026

Rank in USA: #2,847 (Jan 2020) · #2,819 (Jan 2021) · #3,579 (Jan 2022) · #4,291 (Dec 2022) · #4,384 (Jul 2023) · #3,519 (Jan 2024) · #2,235 (Mar 2026) · #3,887 (Aug 2026) · #3,947 (Oct 2026) · #4,076 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
1.7×
Free cash flow yield
-65.0%
Net margin
—
Operating margin
—
Return on equity
-159.2%
Liabilities / assets
43.3%
Revenue growth
+62.5%
R&D / revenue
5873.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Sep 2018: revenue —, net income $-32M—FY18Fiscal year ending Sep 2019: revenue —, net income $-22M—FY19Fiscal year ending Sep 2020: revenue —, net income $-30M—FY20Fiscal year ending Sep 2021: revenue —, net income $-36M—FY21Fiscal year ending Sep 2022: revenue —, net income $-37M—FY22Fiscal year ending Sep 2023: revenue —, net income $-32M—FY23Fiscal year ending Sep 2024: revenue —, net income $-27M—FY24Fiscal year ending Sep 2025: revenue —, net income $-25M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Sep 2025——$-25M$-25M—
Sep 2024——$-26M$-27M—
Sep 2023——$-31M$-32M—
Sep 2022——$-36M$-37M—
Sep 2021——$-36M$-36M—
Sep 2020——$-29M$-30M—
Sep 2019——$-20M$-22M—
Sep 2018——$-17M$-32M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Sep 2025$-17M$0M$-17M$-6.27—
Sep 2024$-19M$0M$-19M$-15.31—
Sep 2023$-23M$0M$-23M$-0.73—
Sep 2022$-18M$1M$-19M$-0.87—
Sep 2021$-19M$9M$-28M$-0.90—
Sep 2020$-15M$3M$-18M$-0.82—
Sep 2019$-16M$-0M$-16M$-0.71—
Sep 2018$-13M$0M$-13M$-1.87—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024 (from the annual report): revenue —, net income $-6M—Sep ’24Three months to Dec 2024: revenue —, net income $-7M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025 (from the annual report): revenue —, net income $-6M—Sep ’25Three months to Dec 2025: revenue —, net income $-5M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of CEL-SCI Corporation with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-25 M
Net income
$-25 M

For year ending September-2025 · source: SEC filing

Balance sheet

Total assets
$28 M
Total liabilities
$12 M
Total equity
$16 M

As of September-2025

Top 44 institutional investors in CEL-SCI Corporation#

As of Sep 30, 2026
44 institutions held 2.0 M shares (about 11.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in CEL-SCI Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC566,328+23,249 (+4.28%)3.22%$1 MNov 13, 2026
2Renaissance Technologies LLC470,869-101,591 (-17.75%)2.68%$1 MNov 12, 2026
3Citadel Advisors LLC162,140-36,360 (-18.32%)0.92%$0 MNov 16, 2026
4Geode Capital Management, LLC130,171+41,971 (+47.59%)0.74%$0 MNov 6, 2026
5MAI Capital Management109,280+1,000 (+0.92%)0.62%$0 MNov 12, 2026
6Vanguard Fiduciary Trust Co102,757+53,721 (+109.55%)0.58%$0 MNov 13, 2026
7Commonwealth Equity Services, LLC55,412+3,978 (+7.73%)0.32%$0 MNov 2, 2026
8Jane Street Group, LLC44,845+8,387 (+23.00%)0.26%$0 MNov 12, 2026
9Osaic Holdings, Inc.44,286+11,506 (+35.10%)0.25%$0 MNov 12, 2026
10XTX Topco Ltd44,020+9,132 (+26.18%)0.25%$0 MNov 16, 2026
11BlackRock, Inc.43,210-51 (-0.12%)0.25%$0 MNov 13, 2026
12Bank Of America Corp /de/40,989+73 (+0.18%)0.23%$0 MNov 16, 2026
13US Bancorp \de\29,9070 (0.00%)0.17%$0 MNov 5, 2026
14State Street Corp27,2700 (0.00%)0.15%$0 MNov 12, 2026
15Raymond James Financial Inc26,013+10,000 (+62.45%)0.15%$0 MNov 12, 2026
16Northern Trust Corp21,141+58 (+0.28%)0.12%$0 MNov 16, 2026
17Gsa Capital Partners LLP15,309New0.09%$0 MNov 16, 2026
18WCG Wealth Advisors LLC12,260New0.07%$0 MNov 16, 2026
19HighTower Advisors, LLC10,0000 (0.00%)0.06%$0 MNov 10, 2026
20Financial Consulate, Inc10,0000 (0.00%)0.06%$0 MOct 23, 2026
21Chilton Capital Management LLC9,1560 (0.00%)0.05%$0 MOct 28, 2026
22UBS Group AG8,520+495 (+6.17%)0.05%$0 MNov 10, 2026
23Morgan Stanley3,041+3,000 (+7317.07%)0.02%$0 MNov 13, 2026
24Tower Research Capital LLC (TRC)1,778New0.01%$0 MNov 16, 2026
25Steward Partners Investment Advisory, LLC6860 (0.00%)0.00%$0 MNov 13, 2026
Show all 44: investors 26 to 44
Institutional investors 26 to 44 in CEL-SCI Corporation
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Global Advisers, LLC5360 (0.00%)0.00%$0 MNov 13, 2026
27Hilton Head Capital Partners, LLC4500 (0.00%)0.00%$0 MOct 23, 2026
28Buck Wealth Strategies, LLC2560 (0.00%)0.00%$0 MOct 28, 2026
29Latitude Advisors, LLC205New0.00%$0 MOct 27, 2026
30Jpmorgan Chase & Co153+146 (+2085.71%)0.00%$0 MNov 12, 2026
31Royal Bank Of Canada145+83 (+133.87%)0.00%$0 MNov 16, 2026
32Jones Financial Companies Lllp66New0.00%$0 MNov 13, 2026
33BNP Paribas Financial Markets410 (0.00%)0.00%$0 MNov 12, 2026
34Alerus Financial NA380 (0.00%)0.00%$0 MNov 9, 2026
35Gables Capital Management Inc.260 (0.00%)0.00%$0 MNov 4, 2026
36Huntington National Bank160 (0.00%)0.00%$0 MNov 10, 2026
37Community Bank, N.A.160 (0.00%)0.00%$0 MNov 6, 2026
38Allworth Financial LP40 (0.00%)0.00%$0 MNov 17, 2026
39Golden State Wealth Management, LLC30 (0.00%)0.00%$0 MNov 2, 2026
40Physician Wealth Advisors, Inc.30 (0.00%)0.00%$0 MOct 20, 2026
41Caitong International Asset Management Co., Ltd3-2 (-40.00%)0.00%$0 MOct 29, 2026
42Tounjian Advisory Partners, LLC20 (0.00%)0.00%$0 MNov 4, 2026
43Mark Sheptoff Financial Planning, LLC1New0.00%$0 MNov 16, 2026
44Jacobi Capital Management LLC1New0.00%$0 MNov 5, 2026

Mutual funds holding CEL-SCI Corporation#

7 funds hold shares worth $1 M (about 3.5% of the company). Since their previous reports 3 added shares and 2 sold, buying $0 M net.
Mutual funds holding CEL-SCI Corporation
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.456,941$0 M2.6%<0.01%+191%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.86,138$0 M0.49%<0.01%+8.5%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC42,461$0 M0.24%<0.01%−0.8%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,164$0 M0.07%<0.01%+10.0%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC11,520$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC7,500$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC45$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at CEL-SCI Corporation#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$867 K
5 purchases, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$867 K
open market only
Insiders on file
10
since
$479 K$0May 2024: bought $81 K (3 trades), sold $0 (0 trades)May 24Jul 2025: bought $220 K (2 trades), sold $0 (0 trades)JulDec 2025: bought $50 K (1 trades), sold $0 (0 trades)DecJan 2026: bought $200 K (1 trades), sold $0 (0 trades)Jan 26May 2026: bought $479 K (2 trades), sold $0 (0 trades)MayAug 2026: bought $138 K (1 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
CEL-SCI Corporation: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Geert R. KerstenChief Executive Officer, DirectorGrant or award+2,621$2.060$5 K318,763Form 4
filed Patricia B. PrichepChief Financial OfficerGrant or award+2,082$2.060$4 K19,571Form 4
filed Eyal TalorChief Scientific OfficerGrant or award+1,165$2.060$2 K10,483Form 4
filed Geert R. KerstenChief Executive Officer, DirectorBuy+100,000$1.380$138 K316,142Form 4
filed Patricia B. PrichepChief Financial OfficerGrant or award+4,125$1.040$4 K17,489Form 4
filed Eyal TalorChief Scientific OfficerGrant or award+2,307$1.040$2 K9,318Form 4
filed Geert R. KerstenChief Executive Officer, DirectorGrant or award+5,192$1.040$5 K216,142Form 4
filed Geert R. KerstenChief Executive Officer, DirectorBuyindirect+300,000$1.200$360 K311,547Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CEL-SCI Corporation#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
705,801
8.8% of shares · 5.96 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-07-28 13:37 UTC, code M, resumed 13:47 UTC
  • 2025-07-11 15:57 UTC, code T3, resumed 16:55 UTC
  • 2025-07-11 15:16 UTC, code M, resumed 15:26 UTC
  • 2025-07-11 13:46 UTC, code M, resumed 13:56 UTC
  • 2025-07-11 13:41 UTC, code M, resumed 13:46 UTC

Fails to deliver

  • : 1,730 shares at $1.50
  • : 1,146 shares at $1.64
  • : 1 shares at $1.62
  • : 580 shares at $2.13
  • : 62 shares at $2.06

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CEL-SCI Corporation scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.6×Price to book 1.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-65.0%Free cash flow is -65.0% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-6.27 vs -15.31Diluted EPS -6.27 in fiscal 2025 against -15.31 the year before (report's currency).
    • ✓Net income higher than five years earlier-$25 M-$25 M in fiscal 2025 against -$30 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$25 MNet income -$25 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-176.3%-176.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.3×Current ratio 2.26 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-38.2×Operating income -38.2 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year125.1%Diluted shares up 125.1% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

CEL-SCI Corporation: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CEL-SCI Corporation: statements by fiscal year
PeriodTrendFY 2025to Sep 30, 2025FY 2024to Sep 30, 2024FY 2023to Sep 30, 2023FY 2022to Sep 30, 2022FY 2021to Sep 30, 2021FY 2020to Sep 30, 2020FY 2019to Sep 30, 2019FY 2018to Sep 30, 2018FY 2017to Sep 30, 2017FY 2016to Sep 30, 2016
Income statement
Research and development1618222523181311r1617r
General and administrative8.98.29.01113128.06.3r5.86.5
Operating expenses25263136363021172124r
Operating income−25−26−31−36−36−29−20−17−21r−24r
Interest expense and finance costs0.60.7r0.71.1—1.2————
Net interest income−0.6−0.7—−1.1−1.1−1.0−1.8——−1.9
Other non-operating income (expense)0.00.2−0.00.1−0.00.0———−1.9r
Income before tax—————−30−22———
Net income including minority interests2527r−32−37r36—————
Net income attributable to shareholders−25−27r−32r−37−36−30−22−32−14−12r
Earnings per share, basic———-0.87-0.90-0.82-0.71-1.87-1.83-2.37r
Earnings per share, diluted-6.27-15.31r-0.73-0.87-0.90r-0.82-0.71-1.87-1.91-2.37r
Shares, weighted average (basic)———43413731177.94.9r
Shares, weighted average (diluted)4.11.8r4443413731177.94.9r
Balance sheet
Cash and cash equivalents114.74.12336168.4102.42.9
Short-term investments———06.20————
Receivables———00.10.10.10.10.20.4
Inventory—1.02.22.02.00.80.80.60.71.0
Current assets126.16.92545189.8114.25.5r
Property, plant and equipment6.18.11012145.816161717r
Right-of-use (leased) assets1.31.51.71.92.11.20———
Other intangible assets0.10.20.20.20.3—0.30.30.20.3
Non-current assets—————1.71.7r———
Total assets28273151764128302325r
Accounts payable1.11.42.01.61.72.01.65.78.23.1
Customer deposits—————————0.0
Debt due within a year2.3—————————
Current liabilities5.14.65.64.73.94.33.09.2114.0
Long-term debt5.7—————————
Lease liabilities (non-current)1.31.41.71.92.01.10———
Total liabilities12141718192122302626r
Retained earnings−539−514−487−455−418−382−354−332−300−285r
Shareholders' equity1613133257205.10.0−3.3−0.7r
Total equity—————————−0.7
Total liabilities and equity28273151764128302325r
Shares outstanding8.02.1r474343393528126.2r
Cash-flow statement
Depreciation and amortization2.12.12.12.00.40.4r0.60.60.60.6r
Share-based compensation1.94.36.31114104.42.71.42.1
Cash from operating activities−17−19−23−18−19−15−16−13−14−23
Capital expenditure−0.0−0.1−0.4−0.6−9.0−2.7r−0.2r−0.0−0.0−0.0
Intangible assets bought0−0.0−0.0−0.0−0.0−0.0r−0.2r−0.1−0.0−0.0
Cash from investing activities−0.0−0.1−0.45.5−15−2.7−0.3−0.1−0.0−0.0
Shares issued28246.6—4714012r1121
Cash from financing activities23204.7−0.6552515211320
Change in cash————217.1−1.97.9−0.5−2.8
Report10-K10-K10-K10-K10-K10-K10-K10-K/A10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at CEL-SCI Corporation#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$920 K
Geert R. Kersten
Other top executives, average
$397 K
the CEO earned 2.3× this
$100 invested is now
$9920
CEL-SCI Corporation: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Geert R. Kersten$920 K$618 K$397 K$9920
2024Geert R. Kersten$1.1 M$912 K$468 K$9650
2023Geert R. Kersten$1.0 M$660 K$368 K$11370

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at CEL-SCI Corporation#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 10 · Shareholder rights changed 2 · Shareholder vote 3

CEL-SCI Corporation: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Material agreement8-K
Shareholder rights changed8-K
Shareholder rights changed8-K
Material agreement8-K
Material agreement8-K
Material agreement8-K
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Directors and officers8-K
Material agreement8-K
Directors and officers8-K
Shareholder vote8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 17, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of CEL-SCI Corporation
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2017$1 MPrivate placement after listingUnder $2 million2optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by CEL-SCI Corporation#

$190 K spent on lobbying the US Congress and federal agencies in 2020, most often on medical/disease research/clinical labs.

Lobbying, 2020
$190 K
#773 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2020
2026 so far
—
  • Medical/Disease Research/Clinical Labs4 reports

Lobbying firms hired in 2020

The Petrizzo Group, Inc. $190 K

CEL-SCI Corporation: lobbying spending by year
YearSpendingOwn lobbyistsReports
2020$190 K—4
2019$100 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cel-Sci Corporation”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How CEL-SCI Corporation compares in Biotechnology

  • Market cap$26 M · higher than 20% of 726
  • Revenue growth62.5% · higher than 77% of 438
  • Price / book1.6× · lower than 63% of 534
  • FCF yield-65.0% · higher than 19% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
CEL-SCI Corporation🇺🇸$26 M——+62.5%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending September-2025
Balance sheet:
As of September-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CEL-SCI Corporation? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CEL-SCI Corporation's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CEL-SCI Corporation? Suggest a correction